A PHASE 2 STUDY OF PEMBROLIZUMAB (MK-3475), DPX-SURVIVAC VACCINE AND LOW DOSE OF CYCLOPHOSPHAMIDE COMBINATION IN PATIENTS WITH ADVANCED OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCER
- Registry ID
- PESCO
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- PRINCESS MARGARET CANCER CENTRE
- Start date
- 2020-04-20
- Last update
- 2017-03-30
Conditions
- OVARIAN CANCER
- PRIMARY PERITONEAL CANCER
- FALLOPIAN TUBE CANCER
Related clinical trials
- A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF SACITUZUMAB TIRUMOTECAN (SAC-TMT, MK-2870) MAINTENANCE TREATMENT WITH OR WITHOUT BEVACIZUMAB VERSUS STANDARD OF CARE IN PARTICIPANTS WITH NEWLY DIAGNOSE ADVANCED HRD-NEGATIVE OVARIAN CANCER FOLLOWING FIRST-LINE PLATINUMBASED CHEMOTHERAPY (TROFUSE-021/ENGOTOV85/GOG-3102)
- A PHASE 1B/2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RALUDOTATUG DERUXTECAN WITH OR WITHOUT OTHER ANTICANCER INVESTIGATIONAL AGENTS IN PARTICIPANTS WITH HIGH-GRADE SEROUS EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCER WHO HAVE RELAPSED AFTER PRIOR PLATINUM-BASED CHEMOTHERAPY
- A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO INVESTIGATE GSK5733584 COMPARED WITH CHEMOTHERAPY IN PARTICIPANTS WITH PLATINUM-RESISTANT OVARIAN CANCER
- A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF SACITUZUMAB TIRUMOTECAN (MK-2870) MAINTENANCE
TREATMENT WITH OR WITHOUT BEVACIZUMAB VERSUS STANDARD OF CARE AFTER
SECOND-LINE PLATINUM-BASED DOUBLET CHEMOTHERAPY IN PARTICIPANTS WITH
PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (TROFUSE-022/ENGOT-OV84/GOG-3103)
- CATALINA-2: A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF TORL-1-23 IN WOMEN WITH ADVANCED PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER (INCLUDING PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCERS) EXPRESSING CLAUDIN 6 (CLDN6)
- A RANDOMIZED PHASE 2 STUDY OF OCULAR TOXICITY EVALUATION AND MITIGATION DURING TREATMENT WITH MIRVETUXIMAB SORAVTANSINE IN PATIENTS WITH RECURRENT OVARIAN CANCER WITH HIGH FOLATE RECEPTOR-ALPHA EXPRESSION
View on source registry